Stimulants, Wakefulness-promoting Agents, and Nonstimulant Attention Deficit Hyperactivity Disorder Medications

Shen Chieh Chang, Winston W. Shen

研究成果: 雜誌貢獻回顧型文獻

3 引文 (Scopus)

摘要

The treatments for attention deficit hyperactivity disorder (ADHD) as well as for excessive daytime sleepiness of narcolepsy, obstructive sleep apnea/hyponea syndrome, and shift work sleep disorder have been advanced and expanded rapidly in the past 15 years. The pharmacotherapeutic armamentaria for those disorders include stimulants (amphetamine, methamphetamine, methylphenidate, and lisdexamfetamine), wakefulness-promoting agents (modafinil and armodafinil for narcolepsy), as well as nonstimulant ADHD medications (atomoxetin, a norepinephrine reuptake inhibitor; guanfacine and clonidine α2A agonists). In this review, a brief history, chemical classifications, and pivotal clinical data of those therapeutic drugs which were approved as indications by the US Food and Drug Administration are discussed. Common off-label applications of those drugs in psychiatric practice are also mentioned.
原文英語
頁(從 - 到)210-216
頁數7
期刊Journal of Experimental and Clinical Medicine(Taiwan)
5
發行號6
DOIs
出版狀態已發佈 - 十二月 2013

指紋

Wakefulness-Promoting Agents
Narcolepsy
Attention Deficit Disorder with Hyperactivity
Circadian Rhythm Sleep Disorders
Guanfacine
Methylphenidate
Methamphetamine
Clonidine
Obstructive Sleep Apnea
Amphetamine
United States Food and Drug Administration
Pharmaceutical Preparations
Psychiatry
Norepinephrine
History
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

引用此文

@article{d2d2d340f4124417a077262fb0a77cc0,
title = "Stimulants, Wakefulness-promoting Agents, and Nonstimulant Attention Deficit Hyperactivity Disorder Medications",
abstract = "The treatments for attention deficit hyperactivity disorder (ADHD) as well as for excessive daytime sleepiness of narcolepsy, obstructive sleep apnea/hyponea syndrome, and shift work sleep disorder have been advanced and expanded rapidly in the past 15 years. The pharmacotherapeutic armamentaria for those disorders include stimulants (amphetamine, methamphetamine, methylphenidate, and lisdexamfetamine), wakefulness-promoting agents (modafinil and armodafinil for narcolepsy), as well as nonstimulant ADHD medications (atomoxetin, a norepinephrine reuptake inhibitor; guanfacine and clonidine α2A agonists). In this review, a brief history, chemical classifications, and pivotal clinical data of those therapeutic drugs which were approved as indications by the US Food and Drug Administration are discussed. Common off-label applications of those drugs in psychiatric practice are also mentioned.",
keywords = "Attention deficit hyperactivity disorder, Modafinil, Narcolepsy, Stimulants",
author = "Chang, {Shen Chieh} and Shen, {Winston W.}",
year = "2013",
month = "12",
doi = "10.1016/j.jecm.2013.10.010",
language = "English",
volume = "5",
pages = "210--216",
journal = "Journal of Experimental and Clinical Medicine",
issn = "1878-3317",
publisher = "Elsevier Taiwan LLC",
number = "6",

}

TY - JOUR

T1 - Stimulants, Wakefulness-promoting Agents, and Nonstimulant Attention Deficit Hyperactivity Disorder Medications

AU - Chang, Shen Chieh

AU - Shen, Winston W.

PY - 2013/12

Y1 - 2013/12

N2 - The treatments for attention deficit hyperactivity disorder (ADHD) as well as for excessive daytime sleepiness of narcolepsy, obstructive sleep apnea/hyponea syndrome, and shift work sleep disorder have been advanced and expanded rapidly in the past 15 years. The pharmacotherapeutic armamentaria for those disorders include stimulants (amphetamine, methamphetamine, methylphenidate, and lisdexamfetamine), wakefulness-promoting agents (modafinil and armodafinil for narcolepsy), as well as nonstimulant ADHD medications (atomoxetin, a norepinephrine reuptake inhibitor; guanfacine and clonidine α2A agonists). In this review, a brief history, chemical classifications, and pivotal clinical data of those therapeutic drugs which were approved as indications by the US Food and Drug Administration are discussed. Common off-label applications of those drugs in psychiatric practice are also mentioned.

AB - The treatments for attention deficit hyperactivity disorder (ADHD) as well as for excessive daytime sleepiness of narcolepsy, obstructive sleep apnea/hyponea syndrome, and shift work sleep disorder have been advanced and expanded rapidly in the past 15 years. The pharmacotherapeutic armamentaria for those disorders include stimulants (amphetamine, methamphetamine, methylphenidate, and lisdexamfetamine), wakefulness-promoting agents (modafinil and armodafinil for narcolepsy), as well as nonstimulant ADHD medications (atomoxetin, a norepinephrine reuptake inhibitor; guanfacine and clonidine α2A agonists). In this review, a brief history, chemical classifications, and pivotal clinical data of those therapeutic drugs which were approved as indications by the US Food and Drug Administration are discussed. Common off-label applications of those drugs in psychiatric practice are also mentioned.

KW - Attention deficit hyperactivity disorder

KW - Modafinil

KW - Narcolepsy

KW - Stimulants

UR - http://www.scopus.com/inward/record.url?scp=84890791157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890791157&partnerID=8YFLogxK

U2 - 10.1016/j.jecm.2013.10.010

DO - 10.1016/j.jecm.2013.10.010

M3 - Review article

AN - SCOPUS:84890791157

VL - 5

SP - 210

EP - 216

JO - Journal of Experimental and Clinical Medicine

JF - Journal of Experimental and Clinical Medicine

SN - 1878-3317

IS - 6

ER -